Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943636 | 1.00 | SRD5A2 (0.59) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29943469 | 0.87 | FLT3 (0.48) | SRD5A2FLT3KDM4EMEN1KMT2A | |
| SCHEMBL29063423 | 0.87 | HDAC3 (0.50) | SRD5A2FLT3KDM4EMEN1KMT2A | |
| SCHEMBL914773 | 0.85 | SRD5A2 (0.59) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL22235474 | 0.85 | FLT3 (0.52) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL914744 | 0.83 | SRD5A2 (0.56) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL24019679 | 0.82 | KMT2A (0.59) | FLT3KDM4EMEN1KMT2AHDAC3 | |
| SCHEMBL30304098 | 0.81 | KDM4E (0.49) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL913914 | 0.80 | FLT3 (0.68) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29414307 | 0.80 | FLT3 (0.68) | SRD5A2FLT3KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041245-A | Preparation method of 4- (difluoromethoxy) -1H-indole-2-carboxylic acid | 上海毕得医药科技股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4635972-A2 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4051265-B1 | FUNCTIONALIZED PEPTIDES CONTAINING TWO PYRROLIDINE RINGS AS ANTICORONAVIRUS AGENTS | ENANTA PHARM INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4051265-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11358953-B2 | Functionalized peptides as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220041652-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112592343-A | Polycyclic compound and application thereof as antiviral drug | 周雨恬 | 2021-04-02 | — | — | CN | disclosed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | SRD5A2 1506/4885FLT3 3680/4885KDM4E 3205/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | SRD5A2 803/4885FLT3 3298/4885KDM4E 2746/4885 |
| US-20220041652-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | SRD5A2 2128/4885FLT3 224/4885KDM4E 3892/4885 |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SRD5A2 1181/4885FLT3 1035/4885KDM4E 963/4885 |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | SRD5A2 2128/4885FLT3 224/4885KDM4E 3892/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | SRD5A2 3702/4885FLT3 2640/4885KDM4E 2930/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | SRD5A2 3702/4885FLT3 2640/4885KDM4E 2930/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SRD5A2 1506/4885FLT3 3680/4885KDM4E 3205/4885 |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | SRD5A2 2128/4885FLT3 224/4885KDM4E 3892/4885 |
| US-11358953-B2 | Functionalized peptides as antiviral agents | SARS1, VIP, ACE | SRD5A2 2128/4885FLT3 224/4885KDM4E 3892/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | SRD5A2 3702/4885FLT3 2640/4885KDM4E 2930/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | SRD5A2 2669/4885FLT3 2239/4885KDM4E 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.